BACKGROUND: The Clinical COPD Questionnaire (CCQ) is a simple patient-reported tool to measure clinical control of chronic obstructive pulmonary disease (COPD). OBJECTIVE: This open-label, single-arm, non-interventional study (NCT03663569) investigated changes in CCQ score during treatment with tiotropium/olodaterol in clinical practice. METHODS: Data were included from consenting COPD patients, enrolled in Bulgaria, Czech Republic, Hungary, Israel, Lithuania, Poland, Romania, Russia, Slovenia, Switzerland and Ukraine, who were receiving a new prescription for tiotropium/olodaterol according to the treating physician in a real-world environment. The primary endpoint was the occurrence of therapeutic success, defined as a 0.4-point decrease in CCQ score after treatment with tiotropium/olodaterol for approximately 6 weeks. RESULTS: Overall, 4819 patients were treated; baseline and Week 6 CCQ scores were available for 4700 patients, mostly classified as Global Initiative for Chronic Obstructive Lung Disease (GOLD) B (51.6%) or D (42.7%). After 6 weeks' treatment, 81.4% (95% confidence interval [95% CI] 80.24-82.49) of patients achieved therapeutic success; mean improvement in overall CCQ score was 1.02 points (95% CI 1.00-1.05). Improved CCQ score was seen in 92.2% of patients (95% CI 91.43-92.98), 2.5% had no change and 5.3% showed a worsening. When stratified by prior treatment, the greatest benefit was seen in treatment-naïve patients, with 85.7% achieving therapeutic success, compared with 79.5% of those pretreated with long-acting β2-agonist (LABA)/inhaled corticosteroid (ICS) and 74.2% of those pretreated with LABA or long-acting muscarinic antagonist (LAMA) monotherapy. Overall, rescue medication decreased by 1.25 puffs/day (95% CI 1.19-1.31) versus baseline. In total, 29 patients (0.6%) reported drug-related adverse events and 7 patients reported serious adverse events (0.15%). CONCLUSION: In 4700 COPD patients, 6 weeks' treatment with tiotropium/olodaterol, as initial treatment or follow-up to LAMA or LABA monotherapy or LABA/ICS, improved CCQ and decreased rescue medication use. The adverse event profile was consistent with the known safety profile of tiotropium/olodaterol.

1 M Sechenov 1st Moscow State Medical University Moscow Russia

Boehringer Ingelheim Pharmaceuticals Inc Ridgefield CT USA

Boehringer Ingelheim RCV GmbH and Co KG Vienna Austria

Bolnišnica Topolšica Topolšica Slovenia

Clinical Pneumophtysiology Hospital Iasi Iasi Romania

Department of Pneumology Faculty of Medicine in Hradec Kralove University Hospital Hradec Kralove Charles University Prague Hradec Kralove Czech Republic

Department of Respiratory and Critical Care Medicine Karl Landsteiner Institute for Lung Research and Pulmonary Oncology Vienna Health Care Group Klinik Floridsdorf Vienna Austria

Faculty of Medicine Clinic of Chest Diseases Immunology and Allergology Institute of Clinical Medicine Vilnius University Vilnius Lithuania

Hadassah Hebrew University Medical Center Jerusalem Israel

Medical Center Sv ivan Rilski OOD Vidin Bulgaria

Petz Aladar County Teaching Hospital Gyor Hungary

Wydział Nauk Medycznych Śląskiego Uniwersytetu Medycznego Katowice Poland

Zürcher RehaZentrum Wald Wald Switzerland

Zobrazit více v PubMed

GBD Disease Injury Incidence Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. PubMed PMC

Mathers CD, Loncar D, Samet J. Projections of global mortality and burden of disease from 2002 to 2030. PubMed DOI PMC

Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. PubMed DOI

Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2020[Updated November25, 2020.]. Available from: https://goldcopd.org/wp-content/uploads/2020/11/GOLD-REPORT-2021-v1.1-25Nov20_WMV.pdf. Accessed November30, 2020.

Wilson MR, Patel JG, Coleman A, McDade CL, Stanford RH, Earnshaw SR. Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model. PubMed DOI PMC

Miravitlles M, Galdiz JB, Huerta A, Villacampa A, Carcedo D, Garcia-Rio F. Cost-effectiveness of combination therapy umeclidinium/vilanterol versus tiotropium in symptomatic COPD Spanish patients. PubMed DOI PMC

Plunkett T, Carty P, O’Neill M, Harrington P, Smith SM, Ryan M. VP19 cost-effectiveness of combination inhaled long-acting bronchodilators. DOI

Hoogendoorn M, Corro Ramos I, Soulard S, et al. PRS30 cost-effectiveness of the fixed-dose combination tiotropium+olodaterol versus tiotropium and Laba/Ics in Finland, Sweden and the Netherlands. DOI

Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. PubMed DOI

Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. PubMed DOI

Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. PubMed DOI

Ferguson GT, Feldman GJ, Hofbauer P, et al. Efficacy and safety of olodaterol once daily delivered via Respimat PubMed DOI PMC

Buhl R, Maltais F, Abrahams R, et al. Tiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4). PubMed DOI PMC

Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. PubMed DOI

Maltais F, Aumann JL, Kirsten A-M, et al. Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD. PubMed DOI PMC

Troosters T, Maltais F, Leidy N, et al. Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease. PubMed DOI

Rabe KF, Chalmers JD, Miravitlles M, et al. Tiotropium/olodaterol delays clinically important deterioration compared with tiotropium monotherapy in patients with early COPD: a post hoc analysis of the TONADO PubMed DOI PMC

Tashkin DP, Amin AN, Kerwin EM. Comparing randomized controlled trials and real-world studies in chronic obstructive pulmonary disease pharmacotherapy. PubMed DOI PMC

Soler-Cataluna JJ, Alcazar-Navarrete B, Miravitlles M. The concept of control of COPD in clinical practice. PubMed DOI PMC

Alma H, de Jong C, Tsiligianni I, Sanderman R, Kocks J, van der Molen T. Clinically relevant differences in COPD health status: systematic review and triangulation. PubMed DOI

Kon SS, Dilaver D, Mittal M, et al. The clinical COPD questionnaire: response to pulmonary rehabilitation and minimal clinically important difference. PubMed DOI

Jones PW, Quirk FH, Baveystock CM. The St George’s respiratory questionnaire. PubMed DOI

Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T. Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. PubMed DOI PMC

van der Molen T, Willemse BW, Schokker S, Ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the clinical COPD questionnaire. PubMed DOI PMC

Soler-Cataluña JJ, Alcázar-Navarrete B, Miravitlles M. The concept of control in COPD: a new proposal for optimising therapy. PubMed DOI

Miravitlles M, Sliwinski P, Rhee CK, et al. Predictive value of control of COPD for risk of exacerbations: an international, prospective study. PubMed DOI

Soler X. Evaluation of changes in control status in COPD: an opportunity for early intervention. PubMed DOI

Zhou Z, Zhou A, Zhao Y, Chen P. Evaluating the clinical COPD questionnaire: a systematic review. PubMed DOI

Strange C, Walker V, DePietro M, et al. Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD. PubMed DOI PMC

Valipour A, Tamm M, Kociánová J, et al. Improvement of self-reported physical functioning with tiotropium/olodaterol in central and Eastern European COPD patients. PubMed DOI PMC

Muro SYH, Kostikas K, Olsson P, Gupta P, Wedzicha JA. Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: a pooled analysis. PubMed DOI PMC

Maleki-Yazdi MR, Singh D, Anzueto A, Tombs L, Fahy WA, Naya I. Assessing short-term deterioration in maintenance-naive patients with COPD receiving umeclidinium/vilanterol and tiotropium: a pooled analysis of three randomized trials. PubMed DOI PMC

Bjermer LH, Kerwin E, Maltais F, et al. Comparative efficacy and safety of umeclidinium/vilanterol, umeclidinium and salmeterol in symptomatic maintenance-naïve and maintenance-treated chronic obstructive pulmonary disease: a pre-specified secondary analysis of the EMAX trial.

Buhl R, de la Hoz A, Xue W, Singh D, Ferguson GT. Efficacy of tiotropium/olodaterol compared with tiotropium as a first-line maintenance treatment in patients with COPD who are naïve to LAMA, LABA and ICS: pooled analysis of four clinical trials. PubMed DOI

Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline. PubMed DOI PMC

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. PubMed DOI PMC

Frith PA, Ashmawi S, Krishnamurthy S, et al. Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non‐frequently exacerbating COPD patients: the FLASH randomized controlled trial. PubMed DOI

Avdeev S, Aisanov Z, Arkhipov V, et al. Withdrawal of inhaled corticosteroids in COPD patients: rationale and algorithms. PubMed DOI PMC

Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. PubMed DOI

Aisanov Z, Avdeev S, Arkhipov V, et al. Russian guidelines for the management of COPD: algorithm of pharmacologic treatment. PubMed DOI PMC

Vukoja M, Kopitovic I, Lazic Z, et al. Diagnosis and management of chronic obstructive pulmonary disease in Serbia: an expert group position statement. PubMed DOI PMC

Ulmeanu R, Fildan AP, Oancea C, Mihaltan F.

Miravitlles M, Anzueto A. A new two-step algorithm for the treatment of COPD. PubMed DOI

Matsunaga K, Oishi K, Miravitlles M, Anzueto A. Time to revise COPD treatment algorithm. PubMed DOI PMC

Ariel A, Altraja A, Belevskiy A, et al. Inhaled therapies in patients with moderate COPD in clinical practice: current thinking. PubMed DOI PMC

Tudoric N, Koblizek V, Miravitlles M, et al. GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) cohort. PubMed DOI

Trinkmann F, Saur J, Borggrefe M, Akin I. Cardiovascular comorbidities in chronic obstructive pulmonary disease (COPD)—current considerations for clinical practice. PubMed DOI PMC

Punekar YS, Sharma S, Pahwa A, Takyar J, Naya I, Jones PW. Rescue medication use as a patient-reported outcome in COPD: a systematic review and regression analysis. PubMed DOI PMC

Rogliani P, Calzetta L, Braido F, et al. LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review. PubMed DOI PMC

Rodrigo GJ, Price D, Anzueto A, et al. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. PubMed DOI PMC

Sharafkhaneh A, Altan AE, Colice GL, et al. A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. PubMed DOI

Steinmetz KO, Abenhardt B, Pabst S, et al. Assessment of physical functioning and handling of tiotropium/olodaterol Respimat PubMed DOI PMC

Taube C, Bayer V, Zehendner CM, Valipour A. Assessment of patient experiences with Respimat PubMed DOI PMC

Davis KH, Su J, Gonzalez JM, et al. Quantifying the importance of inhaler attributes corresponding to items in the patient satisfaction and preference questionnaire in patients using Combivent Respimat. PubMed DOI PMC

Dekhuijzen PN, Lavorini F, Usmani OS. Patients’ perspectives and preferences in the choice of inhalers: the case for Respimat PubMed DOI PMC

Schurmann W, Schmidtmann S, Moroni P, Massey D, Qidan M. Respimat PubMed DOI

Ferguson GT, Buhl R, Bothner U, et al. Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials. PubMed DOI

Tsiligianni IG, van der Molen T, Moraitaki D, et al. Assessing health status in COPD. A head-to-head comparison between the COPD assessment test (CAT) and the clinical COPD questionnaire (CCQ). PubMed DOI PMC

Alma H, de Jong C, Jelusic D, et al. Baseline health status and setting impacted minimal clinically important differences in COPD: an exploratory study. PubMed DOI